Je. Mcmanigle et al., RESPIRATORY EFFECTS PRODUCED BY MICROINJECTION OF L-GLUTAMATE AND AN UPTAKE INHIBITOR OF L-GLUTAMATE INTO THE CAUDAL SUBRETROFACIAL AREA OFTHE MEDULLA, European journal of pharmacology, 280(3), 1995, pp. 257-275
The purposes of our study were to determine the type of respiratory ch
anges that would occur when either an excitatory amino acid receptor a
gonist or an uptake inhibitor was administered into the caudal subretr
ofacial area. This was done by microinjecting either L-glutamate or L-
pyrrolidine-2,4-dicarboxylate (L-trans-2,4-PDC) into the caudal subret
rofacial area while monitoring tidal volume, respiratory rate, mean ar
terial blood pressure and heart rate. Bilateral microinjection of 2.5
nmol of L-glutamate into the caudal subretrofacial area produced apnea
in eight of eight animals tested, and the duration of apnea was 27 +/
- 2 s. To determine the type of L-glutamate receptor responsible for m
ediating the apneic response, antagonists of the N-methyl-D-aspartate
(NMDA) and non-NMDA receptor, namely, 3-[(RS)-carboxypiperazin-4-yl]-p
ropyl-phosphonic acid (CPP), and 6-cyano-7-nitroquinoxaline-2,3-dione
(CNQX), respectively, were tested. Neither antagonist in doses that bl
ocked NMDA (in the case of CPP) and amino-3-hydroxy-5-methyl-isoxazole
-4-propionic acid (AMPA) (in the case of CNQX) blocked apnea elicited
by L-glutamate. In addition, kynurenic acid, an antagonist of NMDA and
non-NMDA ionotropic receptors, failed to block the effect of L-glutam
ate. Microinjection of the metabotropic receptor agonist drug, trans-L
-1-amino-1,3-cyclopentone-dicarboxylic acid (L-trans-ACPD), into the c
audal subretrofacial area failed to have any effect on respiratory act
ivity. Because of the inability to block the effect of L-glutamate in
the caudal subretrofacial area, and the lack of effect of L-trans-ACPD
, the data suggest that the apneic response produced by L-glutamate is
-mediated by an as yet undefined receptor. Microinjection of the L-glu
tamate uptake inhibitor, L-trans-2,4-PDC, was found to produce apnea.
Using the dose of 0.5 nmol of L-trans-2,4-PDC, we examined the type of
excitatory amino acid receptor that mediated the response. Neither pr
etreatment with the NMDA receptor antagonist, CPP, nor the non-NMDA re
ceptor antagonist, CNQX, affected L-trans-2,4-PDC-induced apnea. Howev
er, combined use of these two antagonists prevented L-trans-2,4-PDC-in
duced apnea. These data suggest that the effect of synaptically releas
ed exitatory amino acid at the caudal subretrofacial area on breathing
is apnea, and that this effect is mediated by simultaneous activation
of both NMDA and non-NMDA ionotropic receptors.